Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 11/20 | 0.52 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.52 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16378067 | 1.00 | NR1H2 (0.52) | NR1H2NR1H3SUV39H2GPR119FAAH | |
| SCHEMBL16378104 | 1.00 | NR1H2 (0.52) | NR1H2NR1H3SUV39H2GPR119FAAH | |
| SCHEMBL17375389 | 0.90 | NR1H2 (0.57) | NR1H2NR1H3SUV39H2GPR119FAAH | |
| SCHEMBL17385218 | 0.90 | NR1H2 (0.57) | NR1H2NR1H3SUV39H2GPR119FAAH | |
| SCHEMBL17385245 | 0.89 | NR1H2 (0.56) | NR1H2NR1H3SUV39H2FAAHMAP4K4 | |
| SCHEMBL20139589 | 0.89 | NR1H2 (0.59) | NR1H2NR1H3SUV39H2GPR119FAAH | |
| SCHEMBL16333721 | 0.87 | NR1H3 (0.52) | NR1H2NR1H3SUV39H2GPR119FAAH | |
| SCHEMBL18186172 | 0.86 | NR1H2 (0.53) | NR1H2NR1H3SUV39H2GPR119FAAH | |
| SCHEMBL31342338 | 0.86 | NR1H2 (0.53) | NR1H2NR1H3SUV39H2GPR119FAAH | |
| SCHEMBL30426972 | 0.86 | NR1H2 (0.53) | NR1H2NR1H3SUV39H2GPR119FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3160967-B1 | N-(IMIDAZO[1,2-A]PYRAZIN-6-YL)-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-20180222925-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | Hoffmann-La Roche Inc. and PTC Therapeutics Inc. | 2018-08-09 | — | — | US | disclosed |
| US-20180222925-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | Hoffmann-La Roche Inc. and PTC Therapeutics Inc. | 2018-08-09 | — | — | US | disclosed |
| US-20180222925-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | Hoffmann-La Roche Inc. and PTC Therapeutics Inc. | 2018-08-09 | — | — | US | disclosed |
| US-9975900-B2 | Substituted imidazo[1,2-α]pyrazines for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2018-05-22 | — | — | US | disclosed |
| EP-3013345-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2017-11-22 | — | — | EP | disclosed |
| EP-3013345-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20170197969-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2017-07-13 | — | — | US | disclosed |
| EP-3160967-A1 | IMIDAZO[1,2-A]PYRAZIN-1YL-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG (CH) | 2017-05-03 | — | — | EP | disclosed |
| US-20160145270-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145270-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145270-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-26 | — | — | US | disclosed |
| EP-3013345-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG (CH) | 2016-05-04 | — | — | EP | disclosed |
| WO-2015197503-A1 | IMIDAZO[1,2-A]PYRAZIN-1YL-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-30 | — | — | WO | disclosed |
| WO-2014209841-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014209841-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222925-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, PYGM | NR1H2 604/4885NR1H3 728/4885SUV39H2 2844/4885 |
| US-20170197969-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, PYGM, GYS1 | NR1H2 507/4885NR1H3 612/4885SUV39H2 2019/4885 |
| US-20160145270-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, PYGM | NR1H2 604/4885NR1H3 728/4885SUV39H2 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.